Strategic financial advice grounded in healthcare and life sciences.
Cardiff Advisory advises healthcare and life sciences companies on strategic transactions, partnerships, capital markets, and valuation. Focused sector knowledge informs every engagement.
We work with leadership teams, boards, and investors on decisions where transaction structure, financial considerations, and sector dynamics intersect.
01
M&A and Strategic Advisory
Comprehensive sell- and buy-side support for biopharma and medtech companies seeking growth, partnerships, or exits. We deliver customized transaction strategies, identify ideal partners, and negotiate outcomes that maximize shareholder value.
02
Licensing and Partnering Strategy
We craft strategic licensing frameworks and co-development agreements that align innovation with market access, leveraging Cardiff’s relationships across pharma, biotech, and CDMOs.
03
Valuation and Financial Modeling
Independent, defensible valuations supporting transactions, IP portfolios, and 409A compliance. Our methodologies combine scientific expertise with financial rigor.
04
Capital Formation Advisory
Guidance on structuring private placements, venture rounds, and strategic investments. We connect innovators with aligned investors across healthcare and technology.
05
Fractional CXO Services
Interim corporate development or financial leadership from seasoned executives to accelerate transactions, investor readiness, or strategic pivots.
Our focus
Sector knowledge changes the conversation.
Healthcare and life sciences transactions require more than a conventional financial framework. Clinical development, regulation, intellectual property, reimbursement, commercialization, and capital requirements can materially affect value and deal structure.
Cardiff Advisory focuses exclusively on this sector, connecting the underlying science and business realities with financial and strategic decision-making.
Development and clinical riskUnderstanding how evidence, milestones, and uncertainty shape strategic alternatives.
Commercial and regulatory contextConsidering the market and regulatory conditions that influence transaction economics.
Capital and transaction structureEvaluating financial trade-offs in the context of a company's stage, objectives, and stakeholders.
Our ecosystem
Who works with us?
Cardiff Advisory works at the intersection of healthcare, life sciences, finance, and professional services. Our advisory expertise is relevant to a range of organizations and stakeholders across this ecosystem.
Life sciences & healthcare
Biotech Firms
CDMOs
Clinics
Healthcare Institutions
Hospitals
Medical Device
Pharmaceuticals
Capital & financial advisory
Financial Firms / CPAs
Investment Bankers
Private Equity Firms (PE)
Venture Investors (VC)
Wealth Managers
Commercial Real Estate Firms
Professional services
Audit and Tax Firms
HR Firms
IT Advisors
Law Firms
Management Consulting Firms
Marketing/PR Firms
Research, public & innovation
Government Agencies
Regulatory Agencies
Educational Institutions
Research Centers
Incubators and Accelerators
About Cardiff
Focused advice. Direct engagement.
Cardiff Advisory is a boutique strategic financial advisory firm dedicated to healthcare and life sciences. The firm is founded on the view that sound financial advice in this sector must account for both the underlying science and the realities of capital markets.
David H. Crean, PhD, MBA
Founder & Managing Partner
David H. Crean, PhD, MBA, is Founder and Managing Partner of Cardiff Advisory LLC. He brings more than 30 years of experience across healthcare and life sciences investment banking, mergers and acquisitions, strategic partnering, capital markets, and corporate leadership. His background spans advisory, investment, and operating roles, providing perspective on the decisions facing management teams, boards, and investors. Through his Cardiff Advisory affiliation, Dr. Crean has served as a fractional executive for several life sciences companies, supporting strategic and financial initiatives. He combines scientific training with financial expertise to advise companies on transactions, valuation, capital strategy, and long-term corporate objectives.
Regulatory note: Dr. Crean is a registered representative of BA Securities, LLC, Member FINRA/SIPC. His BA Securities registration has been effective since Aug. 31, 2016. He holds FINRA Series 79 and Series 63 registrations. BrokerCheckRegistration verification↗
Our team and affiliated professionals
Meet the professionals associated with Cardiff Advisory.
John Foley
Head of Marketing and Communications
Sunil Shah, CVA
Manager, Valuation Advisory
Nishma Shah
Head of Valuations
Alexander Johns
Managing Director, Strategy and Commercialization
Our mission and values
Mission, Vision & Values
01 / MISSION
Creating sustainable value.
Our mission is to create and maximize sustainable value for companies in healthcare and life sciences by coupling deep scientific rigor with disciplined strategic financial foresight and expert M&A execution.
02 / VISION
A strategic partner for the journey.
Our vision is to be a leading strategic partner for founders and entrepreneurs as they navigate science-to-market acceleration, capital investment, and financial outcomes.
Our decisions are guided by a fundamental principle: every transaction should create a future enterprise whose value is demonstrably greater than the sum of its previous parts, while also advancing the objectives of owners and stakeholders.
Our origins
Why Cardiff Advisory was founded
Dr. David H. Crean founded Cardiff Advisory in 2020 to address a gap he observed in the strategic advisory and transaction services available to healthcare and life sciences companies. In his experience, founders and entrepreneurs were not always receiving the depth of counsel needed for consequential transactions.
Drawing on more than 30 years across biopharma, investment banking, private equity, and venture capital, Dr. Crean identified two recurring challenges:
Deep domain expertise
Life sciences transactions depend on an understanding of scientific evidence, regulatory pathways, clinical milestones, and commercial realities. Generalist financial advice may not fully capture the risks and opportunities that shape value in this sector.
Senior-level transaction engagement
At larger institutions, day-to-day transaction execution may be delegated to junior teams. Founder-led and lower-middle-market companies often benefit from more direct involvement by experienced senior advisors.
The Cardiff approach
A specialized alternative.
Managing Director-led focus
A boutique, high-touch model built around senior-professional involvement in transaction management, strategic advice, and founder-level decisions.
Integrated scientific and financial acumen
Scientific assessment and financial discipline are brought together to connect clinical and technical promise with market timing, investor expectations, transaction structures, and enterprise value.
Cardiff Advisory seeks to act as a strategic partner combining specialized transaction advice with practical C-suite and founder-level guidance in healthcare and life sciences.
Careers & Culture
Careers at Cardiff Advisory
Our culture is grounded in integrity, sound judgment, intellectual curiosity, and accountability. We value professionals who bring deep expertise, work collaboratively, and take a thoughtful, hands-on approach to serving healthcare and life sciences clients.
Current opportunities
There are no current openings at Cardiff Advisory. When a position becomes available and is announced, we welcome résumés from qualified candidates for that specific role. Please check this page for future opportunities.
Selected Experiences
Relevant transaction experience
The select experiences referenced below relate to the professional career of Cardiff Advisory founder David H. Crean, PhD, MBA, including roles held before founding Cardiff Advisory. It should not be interpreted as a record of transactions completed by Cardiff Advisory LLC. Representative transactions will be added periodically following any required permissions of our clients. Not all transactions are disclosed given the confidential nature of certain private transactions between parties.
Reverse merger2023–24
ImmunogenX→First Wave BioPharma
All-stock acquisition completed March 2024.
Role in Experience: Fractional CBO; sell-side advisor to ImmunogenX.
Licensing & commercialization2022
Turn Therapeutics↔MIMEDX
Wound-care and anti-infective IP license with upfront, milestones and royalties.
Role in Experience: Sell-side advisor to Turn Therapeutics.
Reverse merger2020
Histogen↔Conatus Pharmaceuticals
All-stock combination; Histogen continued as the public company.
Role in Experience: Histogen Board Chairman and Audit Committee Chair.
Company acquisition2019
PermeaDerm→Stedical Scientific
Sale of wound- and burn-care medical device company; terms undisclosed.
Role in Experience: Sell-side advisor through Objective Capital Partners.
Asset sale2019
MabVax→BioNTech
Sale of selected antibody assets and laboratory infrastructure.
Role in Experience: Sell-side advisor through Objective Capital Partners.
Asset valuation2026
Canton Strategic/Gravitas Life Sciences
Fair market valuation of Gravitas Life Sciences assets. Gravitas was later sold by Canton Strategic Holdings (formerly Tharimmune) and subsequently acquired by Hepion Pharmaceuticals in 2026.
Role in Experience: Cardiff Advisory provided valuation services only. Cardiff did not advise on either acquisition or sale.
Enterprise & equity valuation2023
Rady Children's Institute for Genomic Medicine
Business enterprise and equity valuation as of Sept. 30, 2023, supporting an institutional equity financing.
Role in Experience: Cardiff Advisory provided valuation analysis only, not capital placement services.
Contact
Discuss a strategic question.
For inquiries regarding a potential transaction, partnership, capital markets matter, or valuation engagement, please contact Cardiff Advisory.